|
|
|
VGX Pharmaceuticals
to present at the Second International Conference
on Cancer Vaccines/Adjuvants/Delivery
|
| Blue
Bell, PA – October 8, 2007 – |
|
VGX Pharmaceuticals Inc. (VGX) announced today that
Professor David B. Weiner of the University of Pennsylvania and Niranjan
Y. Sardesai, VGX’s Vice President of Product Development, are scheduled
to present at the Second International Conference on Cancer Vaccines/Adjuvants/Delivery
for the Next Decade (CCADD) at The German Cancer Research Center in Heidelberg,
Germany on October 10-12. Dr. Weiner, a VGX co-founder, is a pioneer in
the field of DNA vaccines and is scheduled to present “DNA Vaccination
in the Immunotherapy of Cancer” as part of the Conference’s
Plenary Session. Dr. Sardesai will present “Enhanced Immune Responses
to DNA Vaccines via Adaptive Electroporation” as part of the session
on DNA Vaccines and Electroporation.
The three-day conference will focus on a variety of different approaches
to cancer vaccines, including DNA based vaccination and immunotherapy,
and will include international delegates from biotechnology companies,
major pharmaceutical companies, academic institutions, and government
labs. Over the last two decades, DNA vaccines have become a potent means
of providing immune responses or protective immunity against viruses,
bacteria and parasites in many species from fish to primates, including
humans. Significantly, the first DNA based products in fish and dogs are
on the market. A number of DNA vaccines, comprising plasmid DNA encoding
proteins from pathogens, allergens, and tumors, are being evaluated as
prophylactic vaccines and therapeutic treatments for infectious diseases,
allergies and cancer. The use of DNA as a means of vaccination offers
potential benefits in protective efficacy, cross-strain applicability,
development speed and manufacturing cost compared with conventional vaccines.
Commenting on the conference proceedings, Dr. J. Joseph Kim, CEO and President
of VGX said, “VGX is excited to be presenting at this conference
showcasing the latest advances in cancer vaccines and immunotherapy. Our
pre-clinical research studies demonstrate the broad applicability of our
proprietary electroporation based CELLECTRA™ delivery platform beyond
infectious diseases and into cancer.”
VGX has patented and developed the CELLECTRA™ electroporation device
for the delivery of DNA vaccines and therapeutics. The company’s
DNA-based oncology program includes: VGX-150, a DNA therapeutic, to control
the growth of melanoma and other cancers; VGX-3100, a DNA vaccine targeting
human papilloma virus (HPV) as a therapeutic for cervical cancer; and
VGX-3200, a DNA-based therapeutic for the treatment of cancer related
cachexia and anemia. Pre-clinical data from a mouse model show significant
regression of established melanoma tumors after the introduction of VGX-150,
using electroporation technology. Similarly, VGX has demonstrated regression
of cervical cancer lesions and significant survival in an aggressive mouse
model of cervical cancer when treated with the HPV vaccine compared to
untreated controls. VGX-3100 and VGX-3200 are presently undergoing IND
enabling pre-clinical GLP toxicology studies in combination with the CELLECTRA™
device. The company expects to file an IND for both of these products
in the first quarter of 2008.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule and
biologic product candidates for the treatment of infectious diseases, cancer
and inflammatory diseases. The Company's clinical development programs include
PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection,
both of which are currently in Phase II clinical trials. In addition, VGX
is planning to initiate Phase I clinical studies for VGX-1027, its lead
compound for inflammatory diseases. VGX's research pipeline include a new
generation of DNA vaccines and therapeutics as well as CELLECTRA™,
a patented DNA delivery device. The product candidates and technology programs
are protected by the Company's extensive global intellectual property portfolio.
More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
